索磷布韦在终末期肾病行血液透析治疗合并急性丙型肝炎患者中的安全性和有效性

Jun Dong; Chun Hua Hu; Lin Bai; Rou Zhang; Zhen Tian; Yu Chao Wu; Li Zhu; Dan Feng Ren; Jin Feng Liu; Yuan Yang; Tian Yan Chen; Ying Ren Zhao; Ying Li He

doi:10.7652/jdyxb201903012

索磷布韦在终末期肾病行血液透析治疗合并急性丙型肝炎患者中的安全性和有效性

Translated title of the contribution: Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing hemodialysis

Jun Dong
, Chun Hua Hu
, Lin Bai
, Rou Zhang
, Zhen Tian
, Yu Chao Wu
, Li Zhu
, Dan Feng Ren
, Jin Feng Liu
, Yuan Yang
, Tian Yan Chen
, Ying Ren Zhao
, Ying Li He

The First Affiliated Hospital of Xi’an Jiaotong University
Hospital of Zhen'an County
Xi'an Jiaotong University

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: To evaluate the safety and efficacy of sofosbuvir-based therapy in end-stage renal disease patients undergoing hemodialysis complicated with acute hepatitis C. Methods: Totally 33 subjects who met the inclusion criteria received a half dose of sofosbuvir (200 mg) and a full dose of daclatasvir (90 mg) daily for 24 weeks. Then we detected the levels of HCV RNA, ALT, and TBil at 0, 4, 8, 12, 16, 20, 24, 28, 32 and 36 weeks respectively and evaluated the adverse drug reactions. Results: All the patients made a sustained virological response at 12 weeks after the end of treatment, and there were no drug-related serious adverse events. Conclusion: A half dose of sofosbuvir (200 mg once daily) plus a full dose of daclatasvir (90 mg once daily) was safe and effective for treatment of acute HCV infection in patients who were undergoing ESRD and were on hemodialysis.

Translated title of the contribution	Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing hemodialysis
Original language	Chinese (Traditional)
Pages (from-to)	406-410 and 431
Journal	Journal of Xi'an Jiaotong University (Medical Sciences)
Volume	40
Issue number	3
DOIs	https://doi.org/10.7652/jdyxb201903012
State	Published - May 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.7652/jdyxb201903012

Cite this

Dong, J., Hu, C. H., Bai, L., Zhang, R., Tian, Z., Wu, Y. C., Zhu, L., Ren, D. F., Liu, J. F., Yang, Y., Chen, T. Y., Zhao, Y. R., & He, Y. L. (2019). 索磷布韦在终末期肾病行血液透析治疗合并急性丙型肝炎患者中的安全性和有效性. Journal of Xi'an Jiaotong University (Medical Sciences), 40(3), 406-410 and 431. https://doi.org/10.7652/jdyxb201903012

@article{3c198d3fb34b4bf7b835368e634b910e,

title = "索磷布韦在终末期肾病行血液透析治疗合并急性丙型肝炎患者中的安全性和有效性",

abstract = "Objective: To evaluate the safety and efficacy of sofosbuvir-based therapy in end-stage renal disease patients undergoing hemodialysis complicated with acute hepatitis C. Methods: Totally 33 subjects who met the inclusion criteria received a half dose of sofosbuvir (200 mg) and a full dose of daclatasvir (90 mg) daily for 24 weeks. Then we detected the levels of HCV RNA, ALT, and TBil at 0, 4, 8, 12, 16, 20, 24, 28, 32 and 36 weeks respectively and evaluated the adverse drug reactions. Results: All the patients made a sustained virological response at 12 weeks after the end of treatment, and there were no drug-related serious adverse events. Conclusion: A half dose of sofosbuvir (200 mg once daily) plus a full dose of daclatasvir (90 mg once daily) was safe and effective for treatment of acute HCV infection in patients who were undergoing ESRD and were on hemodialysis.",

keywords = "Acute hepatitis C, Directly-acting antivirals, End-stage renal disease, Hemodialysis, Sofosbuvir",

author = "Jun Dong and Hu, \{Chun Hua\} and Lin Bai and Rou Zhang and Zhen Tian and Wu, \{Yu Chao\} and Li Zhu and Ren, \{Dan Feng\} and Liu, \{Jin Feng\} and Yuan Yang and Chen, \{Tian Yan\} and Zhao, \{Ying Ren\} and He, \{Ying Li\}",

year = "2019",

month = may,

doi = "10.7652/jdyxb201903012",

language = "繁体中文",

volume = "40",

pages = "406--410 and 431",

journal = "Journal of Xi'an Jiaotong University (Medical Sciences)",

issn = "1671-8259",

publisher = "Xi'an Medical University",

number = "3",

}

TY - JOUR

T1 - 索磷布韦在终末期肾病行血液透析治疗合并急性丙型肝炎患者中的安全性和有效性

AU - Dong, Jun

AU - Hu, Chun Hua

AU - Bai, Lin

AU - Zhang, Rou

AU - Tian, Zhen

AU - Wu, Yu Chao

AU - Zhu, Li

AU - Ren, Dan Feng

AU - Liu, Jin Feng

AU - Yang, Yuan

AU - Chen, Tian Yan

AU - Zhao, Ying Ren

AU - He, Ying Li

PY - 2019/5

Y1 - 2019/5

N2 - Objective: To evaluate the safety and efficacy of sofosbuvir-based therapy in end-stage renal disease patients undergoing hemodialysis complicated with acute hepatitis C. Methods: Totally 33 subjects who met the inclusion criteria received a half dose of sofosbuvir (200 mg) and a full dose of daclatasvir (90 mg) daily for 24 weeks. Then we detected the levels of HCV RNA, ALT, and TBil at 0, 4, 8, 12, 16, 20, 24, 28, 32 and 36 weeks respectively and evaluated the adverse drug reactions. Results: All the patients made a sustained virological response at 12 weeks after the end of treatment, and there were no drug-related serious adverse events. Conclusion: A half dose of sofosbuvir (200 mg once daily) plus a full dose of daclatasvir (90 mg once daily) was safe and effective for treatment of acute HCV infection in patients who were undergoing ESRD and were on hemodialysis.

AB - Objective: To evaluate the safety and efficacy of sofosbuvir-based therapy in end-stage renal disease patients undergoing hemodialysis complicated with acute hepatitis C. Methods: Totally 33 subjects who met the inclusion criteria received a half dose of sofosbuvir (200 mg) and a full dose of daclatasvir (90 mg) daily for 24 weeks. Then we detected the levels of HCV RNA, ALT, and TBil at 0, 4, 8, 12, 16, 20, 24, 28, 32 and 36 weeks respectively and evaluated the adverse drug reactions. Results: All the patients made a sustained virological response at 12 weeks after the end of treatment, and there were no drug-related serious adverse events. Conclusion: A half dose of sofosbuvir (200 mg once daily) plus a full dose of daclatasvir (90 mg once daily) was safe and effective for treatment of acute HCV infection in patients who were undergoing ESRD and were on hemodialysis.

KW - Acute hepatitis C

KW - Directly-acting antivirals

KW - End-stage renal disease

KW - Hemodialysis

KW - Sofosbuvir

UR - https://www.scopus.com/pages/publications/85067600201

U2 - 10.7652/jdyxb201903012

DO - 10.7652/jdyxb201903012

M3 - 文章

AN - SCOPUS:85067600201

SN - 1671-8259

VL - 40

SP - 406-410 and 431

JO - Journal of Xi'an Jiaotong University (Medical Sciences)

JF - Journal of Xi'an Jiaotong University (Medical Sciences)

IS - 3

ER -

索磷布韦在终末期肾病行血液透析治疗合并急性丙型肝炎患者中的安全性和有效性

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this